CDK4 and neoplasm: A recent study showed that the combined treatment with CDK4/6 inhibitor and andoncolytic virus-induced immunogenic cell death, enhanced antitumor immunity, inhibited tumor growth, and prolonged the survival of tumor-bearing mice (25).